- Home
- NDAQ vs TAK Comparison
NDAQ vs TAK Comparison
Compare NDAQ & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDAQ
- TAK
- Stock Information
- Founded
- NDAQ 1971
- TAK 1781
- Country
- NDAQ United States
- TAK Japan
- Employees
- NDAQ N/A
- TAK N/A
- Industry
- NDAQ Investment Bankers/Brokers/Service
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- NDAQ Finance
- TAK Health Care
- Exchange
- NDAQ Nasdaq
- TAK Nasdaq
- Market Cap
- NDAQ 50.8B
- TAK 47.5B
- IPO Year
- NDAQ 2002
- TAK N/A
- Fundamental
- Price
- NDAQ $94.03
- TAK $14.37
- Analyst Decision
- NDAQ Buy
- TAK
- Analyst Count
- NDAQ 16
- TAK 0
- Target Price
- NDAQ $92.73
- TAK N/A
- AVG Volume (30 Days)
- NDAQ 3.3M
- TAK 2.9M
- Earning Date
- NDAQ 07-24-2025
- TAK 07-30-2025
- Dividend Yield
- NDAQ 1.16%
- TAK 3.71%
- EPS Growth
- NDAQ 52.22
- TAK N/A
- EPS
- NDAQ 2.60
- TAK 0.45
- Revenue
- NDAQ $8,111,000,000.00
- TAK $30,595,075,281.00
- Revenue This Year
- NDAQ N/A
- TAK $1.01
- Revenue Next Year
- NDAQ $7.24
- TAK $1.04
- P/E Ratio
- NDAQ $35.96
- TAK $64.94
- Revenue Growth
- NDAQ 23.57
- TAK 7.45
- 52 Week Low
- NDAQ $62.43
- TAK $12.80
- 52 Week High
- NDAQ $95.49
- TAK $15.53
- Technical
- Relative Strength Index (RSI)
- NDAQ 69.74
- TAK 40.82
- Support Level
- NDAQ $87.93
- TAK $14.41
- Resistance Level
- NDAQ $95.49
- TAK $14.86
- Average True Range (ATR)
- NDAQ 1.84
- TAK 0.18
- MACD
- NDAQ 0.13
- TAK -0.05
- Stochastic Oscillator
- NDAQ 80.94
- TAK 4.76
About NDAQ Nasdaq Inc.
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its trading business (about 22.5% of sales), the company sells market and financial data to investors, offers Nasdaq-branded indexes, and lists companies through its capital access segment (42.5%). Nasdaq's newest segment, financial technology, was primarily constructed through the acquisitions of Verafin and Adenza and has expanded the company into capital management, financial crime, and regulatory compliance software (35%) as the firm seeks to become a diversified technology company.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.